MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
BeiGene, Ltd. Long Term Debt Current 2011-2026 | BGNE
Annual Long Term Debt Current BeiGene, Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20.7 M | 17.6 M | 22 M | 24 M | 21.9 M | 13.9 M | 10.8 M | 8.73 M | 9.22 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 24 M | 8.73 M | 16.5 M |
Long Term Debt Current of other stocks in the Biotechnology industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aligos Therapeutics
ALGS
|
3.58 M | $ 8.48 | 6.0 % | $ 83.8 M |  USA |
 |
Alterity Therapeutics Limited
ATHE
|
57.6 K | $ 3.66 | -1.48 % | $ 8.81 B |  Australia |
 |
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
316 K | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | USA |
 |
Esperion Therapeutics
ESPR
|
2.1 M | $ 2.19 | 0.92 % | $ 455 M | USA |
 |
Evogene Ltd.
EVGN
|
716 K | $ 0.78 | -4.39 % | $ 27.9 M |  Israel |
 |
Applied Therapeutics
APLT
|
429 K | - | - | $ 8.42 M | USA |
 |
Genmab A/S
GMAB
|
26 M | $ 28.2 | -0.18 % | $ 18 B |  Danmark |
 |
Grifols, S.A.
GRFS
|
117 M | $ 8.38 | 2.01 % | $ 6.83 B |  Spain |
 |
GT Biopharma
GTBP
|
58 K | $ 0.38 | 2.47 % | $ 2.1 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
7.93 M | $ 21.28 | 4.44 % | $ 995 M | USA |
 |
Halozyme Therapeutics
HALO
|
13.3 M | $ 66.92 | -1.33 % | $ 8.02 B | USA |
 |
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K | USA |
 |
Adverum Biotechnologies
ADVM
|
5.67 M | - | - | $ 86.2 M | USA |
 |
Harmony Biosciences Holdings
HRMY
|
1.07 M | $ 29.05 | 0.55 % | $ 1.67 B | USA |
 |
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
215 K | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | USA |
|
Immatics N.V.
IMTX
|
1.88 M | $ 10.87 | 4.17 % | $ 684 M | Germany |
 |
Incyte Corporation
INCY
|
5.7 M | $ 95.33 | -0.77 % | $ 18.6 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
3.55 M | $ 1.46 | 4.29 % | $ 375 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | USA |
 |
Allakos
ALLK
|
3.25 M | - | - | $ 28.6 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
43 K | $ 2.99 | 2.4 % | $ 4.92 M | Israel |
 |
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | USA |
 |
Aquestive Therapeutics
AQST
|
631 K | $ 4.2 | 2.82 % | $ 449 M | USA |
 |
Aravive
ARAV
|
2.2 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
294 K | $ 24.24 | 0.1 % | $ 3.08 B | USA |
 |
AIkido Pharma
AIKI
|
554 K | - | 1.93 % | $ 17.4 M | USA |
 |
Celldex Therapeutics
CLDX
|
1.55 M | $ 32.59 | 1.09 % | $ 2.16 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
4.56 M | $ 1.48 | -0.67 % | $ 394 M |  Britain |
 |
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Cidara Therapeutics
CDTX
|
1.38 M | - | - | $ 1.41 B | USA |
 |
AVROBIO
AVRO
|
878 K | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M | Israel |
 |
AstraZeneca PLC
AZN
|
382 M | - | - | $ 96.9 B | Britain |
 |
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | Germany |
 |
Brainstorm Cell Therapeutics
BCLI
|
208 K | - | -2.5 % | $ 5.88 M | USA |